Brittani Breaux, MD
Endocrinology, Diabetes & Metabolism · Baton Rouge, LANPI 1093134256
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $11,009 of the $17,973 with a category attached, or 61.3%. Novo Nordisk accounts for 74.4% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $11,922, more than ten times the $261 reported in 2019.
Across 266 payments — averaging $67.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$13K
- Medtronic$771
- Lilly USA, LLC$649
- Xeris Pharmaceuticals, Inc.$575
- Dexcom, Inc.$556
- Amgen$436
- plus $2K from 19 others
What the payments were for
- Speaking & faculty fees$11,00961%
- Travel & lodging$6243%
- Food & beverage$6,23635%
- Education$440%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 106 | $13,366 |
| Medtronic(2 entities) | 10 | $771 |
| Lilly USA, LLC | 36 | $649 |
| Xeris Pharmaceuticals, Inc. | 34 | $575 |
| Dexcom, Inc. | 21 | $556 |
| Amgen(2 entities) | 9 | $436 |
| Bayer | 11 | $339 |
| Corcept Therapeutics | 7 | $147 |
| AbbVie | 6 | $138 |
| Insulet Corporation | 1 | $125 |
| BETA Bionics, Inc. | 1 | $124 |
| Ascendis Pharma Endocrinology Inc | 1 | $119 |
| Valeritas, Inc. | 1 | $110 |
| Mannkind Corporation | 3 | $95 |
| Amneal Pharmaceuticals LLC | 5 | $85 |
| Sanofi-aventis U.S. LLC | 3 | $67 |
| Ascensia Diabetes Care US Inc. | 1 | $44 |
| Abbott | 2 | $43 |
| AstraZeneca | 2 | $34 |
| Amphastar Pharmaceuticals, Inc. | 1 | $32 |
| Novartis | 1 | $32 |
| Tandem Diabetes Care, Inc. | 1 | $31 |
| Cequr Corporation | 1 | $24 |
| Boehringer Ingelheim | 1 | $18 |
| Acella Pharmaceuticals, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$11,749
- MINIMED 780G$484
- iLet Bionic Pancreas$371
- EVENITY$255
- DEXCOM G7 GSS (161)$149
- Omnipod$125
- Wegovy$115
- Prolia$110
- V-GO$110
- DEXCOM G6 TRANSMITTER$107
How this compares
$17,973 in reported general payments places this provider in the 75th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 213 | $254,556 |
| MounjaroTirzepatide | 109 | $147,539 |
| JardianceEmpagliflozin | 77 | $82,918 |
| JanuviaSitagliptin Phosphate | 42 | $31,754 |
| TradjentaLinagliptin | 33 | $19,737 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 14 | $17,071 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 22 | $14,367 |
| RybelsusSemaglutide | 11 | $12,408 |
| TrulicityDulaglutide | 13 | $11,935 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $9,983 |
| Gvoke Hypopen 2-PackGlucagon | 16 | $9,699 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $8,416 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $6,388 |
| SynthroidLevothyroxine Sodium | 65 | $6,024 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 51 | $4,875 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $13,366 | $266,964224 claims |
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $649 | $160,691135 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $18 | $119,727124 claims |
| AbbVieSynthroid | $138 | $6,02465 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $85 | $1,176153 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Baton Rouge
- Timothy GilbertBaton Rouge$985K
- Frank GreenwayBaton Rouge$42K
- Ivan GamboaBaton Rouge$25K
- Jonathan WeldenBaton Rouge$24K
- Lourdes RodriguezBaton Rouge$17K
- Robin KilpatrickBaton Rouge$12K
- Lauren CutroneBaton Rouge$11K
- Jolene JohnsonBaton Rouge$10K
- Shatha MuradBaton Rouge$2K
- Roopitha KavalBaton Rouge$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.